MANNATECH Maintains Compliance, Reports 1.9M Shares Outstanding

TL;DR

**MTEX is a small, compliant player in health products; watch for actual financials, as this filing is light on performance data.**

AI Summary

MANNATECH INC (MTEX) reported its 10-Q for the quarter ended June 30, 2025. The filing indicates the company is a smaller reporting company and a non-accelerated filer, suggesting a smaller market capitalization and potentially less stringent reporting requirements compared to larger entities. As of August 5, 2025, the company had 1,900,930 shares of common stock outstanding, with a par value of $0.0001 per share. The company operates under the SIC code 2833, Medicinal Chemicals & Botanical Products, indicating its primary business is in health and wellness products. The filing confirms MANNATECH has met all SEC filing requirements for the preceding 12 months and has submitted all required Interactive Data Files. Specific revenue and net income figures were not provided in the excerpt, but the operational details confirm its status and compliance. The strategic outlook and key business changes are not detailed in this initial section of the filing.

Why It Matters

For investors, MANNATECH's status as a smaller reporting company and non-accelerated filer means it may have different growth trajectories and risk profiles compared to larger competitors in the medicinal chemicals and botanical products sector. The 1,900,930 shares outstanding as of August 5, 2025, is a critical data point for calculating market capitalization and per-share metrics, directly impacting valuation. Employees and customers might see this as a stable, compliant operation, but the lack of detailed financial performance in this section means competitive positioning remains unclear. The broader market will note its continued compliance with SEC regulations, which is a baseline expectation for any publicly traded entity.

Risk Assessment

Risk Level: medium — The risk level is medium because while the company demonstrates compliance with SEC regulations, the provided excerpt lacks specific financial performance data such as revenue, net income, or cash flow. This absence makes it difficult to assess the company's operational health and financial stability, which are crucial for investors. The status as a 'smaller reporting company' can also imply higher volatility and less liquidity compared to larger firms.

Analyst Insight

Investors should hold off on making any definitive decisions based solely on this filing. Seek out the full financial statements within the 10-Q to analyze revenue trends, profitability, and cash flow before considering any investment in MTEX. Focus on the company's growth strategy within the competitive medicinal chemicals market.

Key Numbers

• 1,900,930 — Shares Outstanding (As of August 5, 2025, this number is crucial for market capitalization calculations.)
• $0.0001 — Par Value Per Share (This low par value indicates the nominal value of each share.)
• 2025-06-30 — Quarter End Date (The period for which the financial results are reported.)
• 2025-08-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 972-471-7400 — Business Phone Number (Direct contact for the company's principal executive offices.)

Key Players & Entities

• MANNATECH INCORPORATED (company) — Registrant as specified in its Charter
• MTEX (company) — Trading Symbol on The Nasdaq Stock Market LLC
• SEC (regulator) — Securities and Exchange Commission
• The Nasdaq Stock Market LLC (company) — Exchange where Common Stock is registered
• $0.0001 (dollar_amount) — Par value per share of common stock
• 1,900,930 (dollar_amount) — Number of shares outstanding as of August 5, 2025
• June 30, 2025 (date) — End of the quarterly period reported
• August 12, 2025 (date) — Date of filing
• Flower Mound, Texas (location) — Address of Principal Executive Offices
• 000-24657 (identifier) — Commission File No.

FAQ

Industry Context

Mannatech, Inc. operates within the Medicinal Chemicals & Botanical Products sector (SIC 2833), which encompasses companies focused on health and wellness products derived from natural sources. This industry is characterized by evolving consumer preferences for natural and organic ingredients, as well as increasing regulatory scrutiny regarding product claims and manufacturing practices.

Regulatory Implications

As a smaller reporting company and non-accelerated filer, Mannatech, Inc. benefits from scaled disclosure requirements. However, it must still adhere to all SEC filing requirements, including the timely submission of its 10-Q and Interactive Data Files, to maintain compliance.

What Investors Should Do

1. Monitor future 10-Q filings for detailed financial performance metrics.
2. Research industry trends in the health and wellness sector.

Key Dates

• 2025-06-30: Quarterly period ended — This date marks the end of the reporting period for the 10-Q filing.
• 2025-08-12: 10-Q Filing Date — Indicates the official submission date of the quarterly report to the SEC.
• 2025-08-05: Shares Outstanding Record Date — Establishes the number of shares outstanding as of this date for reporting purposes.

Glossary

Smaller Reporting Company

A company that meets certain criteria for revenue, public float, and filing history, allowing for scaled disclosure requirements. (Mannatech, Inc. is identified as a smaller reporting company, indicating it may have less stringent reporting obligations compared to larger filers.)

Non-accelerated filer

A type of filer that is not required to meet the accelerated filer deadlines for SEC filings. (This classification for Mannatech, Inc. suggests a smaller market capitalization and potentially less frequent or stringent reporting compared to accelerated filers.)

SIC code 2833

Standard Industrial Classification code for Medicinal Chemicals & Botanical Products. (This code categorizes Mannatech, Inc.'s primary business operations within the health and wellness product sector.)

Interactive Data File

Data submitted to the SEC in a machine-readable format, typically using XBRL (eXtensible Business Reporting Language). (Mannatech, Inc. has confirmed submission of these files, indicating compliance with modern SEC electronic filing standards.)

Year-Over-Year Comparison

This excerpt does not contain comparative financial data from previous filings, making it impossible to assess year-over-year changes in revenue, net income, margins, or other key financial metrics. Information regarding new or evolving risk factors compared to prior periods is also not available in this section.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share MTEX The Nasdaq Stock Market
• $939 — ccounts receivable, net of allowance of $939 and $935 409 19 Income tax receivable
• $935 — eceivable, net of allowance of $939 and $935 409 19 Income tax receivable 734 737
• $0.01 — Shareholders' equity Preferred stock, $0.01 par value, 1,000,000 shares authorized,
• $5.5 million — ivalents. Cash and cash equivalents was $5.5 million at June 30, 2025 and $11.4 million at D
• $11.4 million — s was $5.5 million at June 30, 2025 and $11.4 million at December 31, 2024. The Company inclu
• $2.0 million — 31, 2024, credit card receivables were $2.0 million and $1.6 million, respectively, and cas
• $1.6 m — card receivables were $2.0 million and $1.6 million, respectively, and cash and cash
• $2.5 million — k accounts in foreign countries totaled $2.5 million and $5.1 million at June 30, 2025 and D
• $5.1 million — eign countries totaled $2.5 million and $5.1 million at June 30, 2025 and December 31, 2024,
• $1.2 million — 31, 2024, our total restricted cash was $1.2 million and $1.1 million, respectively. The fo
• $1.1 m — al restricted cash was $1.2 million and $1.1 million, respectively. The following tab
• $0.9 million — held an allowance for credit losses of $0.9 million and $1.4 million, respectively. June
• $1.4 m — e for credit losses of $0.9 million and $1.4 million, respectively. June 30, 2025 Ju
• $0 — lated to product orders in transit were $0 at each of June 30, 2025 and December 3

Filing Documents

• mtex0630202510-q.htm (10-Q) — 1018KB
• mtexq2202510-qexh311.htm (EX-31.1) — 11KB
• mtexq2202510-qexh312.htm (EX-31.2) — 11KB
• mtexq2202510-qexh321.htm (EX-32.1) — 6KB
• mtexq2202510-qexh322.htm (EX-32.2) — 6KB
• 0001056358-25-000075.txt ( ) — 1051KB

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 2 Condensed Consolidated Balance Sheets (unaudited) 2 Condensed Consolidated Statements of Operations (unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss (unaudited) 3 Condensed Consolidated Statements of Shareholders' Equity (unaudited) 4 Condensed Consolidated Statements of Cash Flows (unaudited) 5 Notes to Condensed Consolidated Financial Statements (unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Company Overview 22 Results of Operations 24 Liquidity and Capital Resources 31 Significant Accounting Policies and Critical Estimates 33

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 35

Controls and Procedures

Item 4. Controls and Procedures 35

– OTHER INFORMATION

Part II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 37

Risk Factors

Item 1A. Risk Factors 37

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 38

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 38

Other Information

Item 5. Other Information 38

Exhibits

Item 6. Exhibits 38

Signatures

Signatures 40 Special Note Regarding Forward-Looking Statements Certain disclosures and analyses in this Form 10-Q, including information incorporated by reference, may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995 that are subject to various risks and uncertainties. Opinions, forecasts, projections, guidance, or other statements other than statements of historical fact are considered forward-looking statements and reflect only current views about future events and financial performance. Some of these forward-looking statements include statements regarding management's plans and objectives for future operations existing cash flows being adequate to fund future operational needs future plans related to budgets, future capital requirements, market share growth, and anticipated capital projects and obligations the realization of net deferred tax assets the ability to curtail operating expenditures global statutory tax rates remaining unchanged the impact of future market changes due to exposure to foreign currency translations the possibility of certain policies, procedures, and internal processes minimizing exposure to market risk the impact of new accounting pronouncements on financial condition, results of operations, or cash flows the outcome of new or existing litigation matters the outcome of new or existing regulatory inquiries or investigations other assumptions described in this report underlying such forward-looking statements. Although we believe that the expectations included in these forward-looking statements are reasonable, these forward-looking statements are subject to certain events, risks, assumptions, and uncertainties, including those discussed below, the "Risk Factors" section in Part I, Item 1A of our

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements MANNATECH, INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS – (UNAUDITED) (in thousands, except share and per share amounts) ASSETS June 30, 2025 December 31, 2024 Cash and cash equivalents $ 5,525 $ 11,396 Restricted cash 550 550 Accounts receivable, net of allowance of $939 and $935 409 19 Income tax receivable 734 737 Inventories, net 12,587 10,405 Prepaid expenses and other current assets 1,890 1,755 Deferred commissions 730 1,259 Total current assets 22,425 26,121 Property and equipment, net 2,947 2,858 Operating lease right-of-use assets 2,059 2,094 Other assets 2,961 2,644 Deferred tax assets, net 1,780 1,770 Long-term restricted cash 610 569 Total assets $ 32,782 $ 36,056 LIABILITIES AND SHAREHOLDERS' EQUITY Commissions and incentives payable $ 6,427 $ 8,642 Accrued expenses 3,828 3,832 Deferred revenue 2,046 3,027 Accounts payable 5,402 2,070 Current portion of operating lease liabilities 1,085 1,178 Taxes payable 1,147 1,788 Current notes payable — 84 Current portion of finance lease liabilities 284 275 Total current liabilities 20,219 20,896 Long-term notes payable 2,900 2,900 Operating lease liabilities, excluding current portion 1,562 1,576 Other long-term liabilities 1,600 1,390 Finance lease liabilities, excluding current portion 537 680 Total liabilities 26,818 27,442 Commitments and contingencies Shareholders' equity Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding — — Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issu ed and 1,900,930 s hares outstanding as of June 30, 2025 and 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024 — — Additional paid-in capital 33,074 33,027 (Accumulated deficit) retained earnings (4,653) 1,189 Accumulated other comprehensive loss (2,895) (5,666) Treasury stock, at average cost, 841,927 s hares as of June 30, 2025 a

View Full Filing

View this 10-Q filing on SEC EDGAR